Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

An Erratum to this article was published on 13 April 2014

Abstract

Renal or hepatic impairment, often encountered in patients with type 2 diabetes, influences the pharmacokinetics and bioavailability of antihyperglycemic agents. An emerging concern is whether pharmacotherapy with incretin-based agents, the most recent drug classes to be introduced for type 2 diabetes, can be safely used in patients with renal insufficiency or hepatic damage. This literature review examines the results of studies on these novel drug classes, with a view to provide the practitioner with a balanced, evidence-based position when considering incretin-based therapies in patients with type 2 diabetes and impaired kidney or liver function. All currently available dipeptidyl peptidase-4 (DPP-4) inhibitors appear to be appropriate pharmacotherapeutic choices in patients with declining renal function, with linagliptin affording the added advantage of not requiring dose adjustment or periodic monitoring of drug-related kidney function. In contrast, caution is warranted with the use of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with moderate or severe renal impairment. The slightly wider evidence base for liraglutide than for exenatide or lixisenatide is not sufficient to support its use in severe renal impairment. What little evidence there is for incretin-based therapies in hepatic impairment has come from a few past hoc analysis of clinical trials, with most precautions and warnings reflecting the paucity of knowledge about incretin efficacy or safety in this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl 2): S12-154

    Google Scholar 

  2. C.E. Koro, B.H. Lee, S.J. Bowlin, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin. Ther. 31(11), 2608–2617 (2009)

    Article  PubMed  Google Scholar 

  3. J.L. Meyers, S.D. Candrilli, B. Kovacs, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad. Med. 123(3), 133–143 (2011)

    PubMed  Google Scholar 

  4. National Diabetes Fact Sheet 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta, GA

  5. G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, F. Cavalot, M. Cignarelli, L. Laviola, S. Morano, A. Nicolucci, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J. Hypertens. 29(9), 1802–1809 (2011)

    Article  CAS  PubMed  Google Scholar 

  6. G. Pugliese, A. Solini, C. Fondelli, R. Trevisan, M. Vedovato, A. Nicolucci, Penno G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrol. Dial. Transplant. 26(12), 3950–3954 (2011)

    Article  CAS  PubMed  Google Scholar 

  7. G.L. Bakris, Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin. Proc. 86(5), 444–456 (2011)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. S.K. Majumdar, S.E. Inzucchi, Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 44(1), 47–58 (2013)

    Article  CAS  PubMed  Google Scholar 

  9. Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract (1995). 2012 Apr;40(2):7-21

  10. N.V. Niemeyer, L.M. Janney, Thiazolidinedione-induced edema. Pharmacotherapy 22, 924–929 (2002)

    Article  PubMed  Google Scholar 

  11. A.J. Krentz, R.E. Ferner, C.J. Bailey, Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11(4), 223–241 (1994)

    Article  CAS  PubMed  Google Scholar 

  12. Aires Neto P, Gomes HV, Campos M. Management of hyperglycemia in patients with chronic kidney disease. J Nephrol. 2013 Jul-Aug;26(4):629-35

  13. I. Mühlhauser, G. Toth, P.T. Sawicki, M. Berger, Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14, 344–346 (1991)

    Article  PubMed  Google Scholar 

  14. H.B. El-Serag, T. Tran, J.E. Everharts, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468 (2004)

    Article  PubMed  Google Scholar 

  15. P.S. Hsieh, Y.J. Hsieh, Impact of liver diseases on the development of type 2 diabetes mellitus. World J. Gastroenterol. 17(48), 5240–5245 (2011)

    Article  PubMed Central  PubMed  Google Scholar 

  16. I. Balik, N. Yilmaz, N. Turkcapar, H. Yasa, Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30, 584 (1999)

    Article  CAS  PubMed  Google Scholar 

  17. D.J. Drucker, S.I. Sherman, F.S. Gorelick, R.M. Bergenstal, R.S. Sherwin, J.B. Buse, Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2), 428–433 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. C.F. Deacon, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13(1), 7–18 (2011)

    Article  CAS  PubMed  Google Scholar 

  19. J.A. Davidson, J. Brett, A. Falahati, D. Scott, Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 17(3), 345–355 (2011)

    Article  PubMed  Google Scholar 

  20. A.J. Scheen, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab. 12(8), 648–658 (2010)

    Article  CAS  PubMed  Google Scholar 

  21. Saxagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf. Last access January 8, 2014

  22. Linagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Last access January 8, 2014

  23. Sitagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Last access January 8, 2014

  24. Vildagliptin Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf. Last access January 8, 2014

  25. R. Christopher, P. Covington, Davenport M.P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30, 513–527 (2008)

    Article  CAS  PubMed  Google Scholar 

  26. P. Covington, R. Christopher, M. Davenport, P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 30, 499–512 (2008)

    Article  CAS  PubMed  Google Scholar 

  27. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy 2013:7 989–1001

    Google Scholar 

  28. Exenatide Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf. Last access January 8, 2014

  29. Liraglutide Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf

  30. U. Graefe-Mody, C. Friedrich, A. Port, A. Ring, S. Retlich, T. Heise, A. Halabi, H.J. Woerle, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes. Metab. 13(10), 939–946 (2011)

    Article  CAS  PubMed  Google Scholar 

  31. Friedrich C, Emser A, Woerle HJ, Graefe-Mody U. Renal Impairment Has No Relevant Effect on Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes Mellitus. 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011. Poster: 1105-P

  32. D.W. Boulton, L. Li, E.U. Frevert, A. Tang, L. Castaneda, N.N. Vachharajani, D.M. Kornhauser, C.G. Patel, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet. 50(4), 253–265 (2011)

    Article  CAS  PubMed  Google Scholar 

  33. D. Boulton, A. Tang, C. Patel et al., Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Endocrine Abstracts 20, P357 (2009)

    Google Scholar 

  34. A.J. Bergman, J. Cote, B. Yi, T. Marbury, S.K. Swan, W. Smith, K. Gottesdiener, J. Wagner, G.A. Herman, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30, 1862–1864 (2007)

    Article  CAS  PubMed  Google Scholar 

  35. A. Karim, P. Fleck, L. Hetman et al., Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P). Diabetes 57(Suppl. 1), A160 (2008)

    Google Scholar 

  36. Y.L. He, B. Flannery, Y. Wang et al., The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86). Clin. Pharmacol. Ther. 81(Suppl. 1), S113 (2007)

    Google Scholar 

  37. Arjona Ferreira JC, Yu Q, Golm G, McCrary Sisk C, Williams-Herman D. High Correlation between Estimated Glomerular Filtration Rate and Estimated Creatinine Clearance for Sitagliptin Dose Selection in Patients with Renal Insufficiency. 2011 ADA

  38. H. Linnebjerg, P.A. Kothare, S. Park, K. Mace, S. Reddy, M. Mitchell, R. Lins, Effect of renal impairment on the pharmacokinetics of exenatide. Br. J. Clin. Pharmacol. 64(3), 317–327 (2007)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Liu YH, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Diabetes. 2009;58(Suppl. 1):Abstract 557-P

  41. Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012 Jan 13

  42. C. Patel, L. Castaneda, U. Frevert, L. Li, D.M. Kornhauser, D.W. Boulton, Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects (Abstract 537-P). Diabetes 57(Suppl. 1), A160 (2008)

    Google Scholar 

  43. E.M. Migoya, C.H. Stevens, A.J. Bergman, W.L. Luo, K.C. Lasseter, S.C. Dilzer, M.J. Davies, J.A. Wagner, G.A. Herman, Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 16, e165–e170 (2009)

    PubMed  Google Scholar 

  44. Y.L. He, R. Sabo, J. Campestrini, Y. Wang, M. Ligueros-Saylan, K.C. Lasseter, S.C. Dilzer, D. Howard, W.P. Dole, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur. J. Clin. Pharmacol. 63, 677–686 (2007)

    Article  CAS  PubMed  Google Scholar 

  45. Karim A, Fleck P, Dorsey D et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment (Abstract). J Clin Pharmacol 2007; 47: Abstract 107

  46. A. Flint, K. Nazzal, P. Jagielski, C. Hindsberger, M. Zdravkovic, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br. J. Clin. Pharmacol. 70(6), 807–814 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Cooper M, von Eynatten M, Emser A, Patel S, Woerle HJ. Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes With or Without Renal Function Decline: Results From a Global Phase 3 Program. Poster: 1068-P, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011

  48. S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, K.A. Dugi, Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 13(3), 258–267 (2011)

    Article  PubMed  Google Scholar 

  49. u Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K.A. Dugi, H.J. Woerle, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 13(1), 65–74 (2011)

    Article  CAS  PubMed  Google Scholar 

  50. D.R. Owens, R. Swallow, K.A. Dugi, H.J. Woerle, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet. Med. 28(11), 1352–1361 (2011)

    Article  CAS  PubMed  Google Scholar 

  51. McGill Janet b., Lance Sloan, Jennifer Newman, Sanjay Patel, Christophe Sauce, Maximilian Von Eynatten, Hans-Juergen Woerle, Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetes Care Publish Ahead of Print, published online October 1, 2012

  52. J.C. Chan, R. Scott, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555 (2008)

    Article  CAS  PubMed  Google Scholar 

  53. V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947–954 (2011)

    Article  CAS  PubMed  Google Scholar 

  54. V. Lukashevich, A. Schweizer, J.E. Foley, S. Dickinson, P.H. Groop, W. Kothny, Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 9, 21–28 (2013)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukashevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). EASD 2011

  56. M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes. Metab. 13(6), 523–532 (2011)

    Article  CAS  PubMed  Google Scholar 

  57. M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson, K.M. Schützer, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int. J. Clin. Pract. 65(12), 1230–1239 (2011)

    Article  CAS  PubMed  Google Scholar 

  58. Y. Nakamura, M. Inagaki, T. Shimizu, K. Fujita, M. Inoue, H. Gotoh, K. Oguchi, Y. Goto, Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study. Nephron Clin Pract 123, 46–51 (2013). doi:10.1159/00035167

    Article  CAS  PubMed  Google Scholar 

  59. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013 Sep;36(9):2543-50. doi: 10.2337/dc12-2006. Epub 2013 Mar 27

  60. Sloan L, Newman J, Sauce C, von Eynatten M, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients With Severe Renal Impairment. Poster: 413-PP, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24–28, 2011

  61. H. Yanai, H. Adachi, H. Hamasaki, Y. Masui, R. Yoshikawa, S. Moriyama, S. Mishima, A. Sako, Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res. 4(4), 251–258 (2012)

    CAS  PubMed Central  PubMed  Google Scholar 

  62. W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032–1039 (2012)

    Article  CAS  PubMed  Google Scholar 

  63. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013 Apr 24;6:161-70. doi: 10.2147/DMSO.S28951. Print 2013

  64. Alogliptin. Highlights of prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Last access January 8, 2014

  65. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012, Jan 23

  66. U.S. Food and Drug Administration. Information for healthcare professionals; reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113705.htm. Accessed June 09, 2013

  67. W.J. Weise, M.S. Sivanandy, C.A. Block, R.J. Comi, Exenatide-associated ischemic renal failure. Diabetes Care 32, 22–23 (2009)

    Article  Google Scholar 

  68. H. Nandakoban, T.J. Furlong, J.R. Flack, Acute tubulointerstitial nephritis following treatment with exenatide. Diabet. Med. 30(1), 123–125 (2013). doi:10.1111/j.1464-5491.2012.03738.x

    Article  CAS  PubMed  Google Scholar 

  69. Y. Kaakeh, S. Kanjee, K. Boone, J. Sutton, Liraglutide-induced acute kidney injury. Pharmacotherapy 32(1), e7–e11 (2012)

    Article  PubMed  Google Scholar 

  70. N.R. Pinelli, C.L. Moore, S. Tomasello, Incretin-based therapy in chronic kidney disease. Adv Chronic Kidney Dis 17(5), 439–449 (2010)

    Article  PubMed  Google Scholar 

  71. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, L. Ping, J. Ye, J. Rosenstock, Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36(9), 2489–2496 (2013)

    Article  CAS  PubMed  Google Scholar 

  72. J. Rosenstock, D. Raccah, L. Korányi, L. Maffei, G. Boka, P. Miossec, J.E. Gerich, Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36(10), 2945–2951 (2013)

    Article  CAS  PubMed  Google Scholar 

  73. Lixisenatide. Summary of product characteristics. http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/002445/WC500140401.pdf. Last access January 8, 2014

  74. Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukasevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia Volume 54 (1) Springer Journals – Sep 1, 2011. A(819)

  75. D.J. Cuthbertson, A. Irwin, C.J. Gardner, C. Daousi, T. Purewal, N. Furlong, N. Goenka, E.L. Thomas, V.L. Adams, S.P. Pushpakom, M. Pirmohamed, G.J. Kemp, Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 7(12), e50117 (2012)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effect. Expert Opinion on Drug Safety Jan 2013, Vol. 12, No. 1: 103–109

Download references

Conflict of interest

CBG discloses teaching and speaking fees from Merck, Novo Nordisk, BMS/AZ Alliance, and BI/Lilly Alliance. All the other authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Metabolism and Diabetes Unit, ASL TO5, Regione Piemonte, Chieri, Italy

    Carlo B. Giorda

  2. Chaira Medica Association, Chieri, Italy

    Elisa Nada & Barbara Tartaglino

Authors
  1. Carlo B. Giorda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisa Nada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Tartaglino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo B. Giorda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giorda, C.B., Nada, E. & Tartaglino, B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46, 406–419 (2014). https://doi.org/10.1007/s12020-014-0179-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0179-0

Keywords

Search

Navigation